<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Cetuximab was approved using a weekly schedule, alone or in combination with chemotherapy (CT) </plain></SENT>
<SENT sid="1" pm="."><plain>However, many CT regimens in <z:e sem="disease" ids="C0948380" disease_type="Neoplastic Process" abbrv="">metastatic colorectal cancer</z:e> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e>) are delivered every 2 weeks (q2wks) </plain></SENT>
<SENT sid="2" pm="."><plain>Preliminary data suggested that a simplified schedule using cetuximab q2wks, 500 mg/mÂ² would be equivalent to the standard weekly administration </plain></SENT>
<SENT sid="3" pm="."><plain>Medical data of <z:hpo ids='HP_0000001'>all</z:hpo> patients with advanced <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> who received cetuximab q2wks were retrospectively collected and checked for consistency by an independent monitor in 4 European centers </plain></SENT>
<SENT sid="4" pm="."><plain>Ninety-one patients were treated between 2005 and 2007 when the K-<z:mp ids='MP_0011356'>RAS</z:mp> mutational status of <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> was not determined routinely </plain></SENT>
<SENT sid="5" pm="."><plain>They received a median of 4 (0-5) previous drugs, including previous weekly cetuximab in 38.5% of patients </plain></SENT>
<SENT sid="6" pm="."><plain>Cetuximab q2wks was associated with an irinotecan-based regimen in 85.7% of patients </plain></SENT>
<SENT sid="7" pm="."><plain>The median number of cetuximab administrations was 6 (1-23) </plain></SENT>
<SENT sid="8" pm="."><plain><z:e sem="disease" ids="C1167791" disease_type="Disease or Syndrome" abbrv="">Skin toxicity</z:e> was observed in 68.2% of evaluable patients (grade 3 in 15%) </plain></SENT>
<SENT sid="9" pm="."><plain>Only one grade 1 allergy was reported </plain></SENT>
<SENT sid="10" pm="."><plain>In the 84 patients beyond first-line therapy, response rate was 29.3% </plain></SENT>
<SENT sid="11" pm="."><plain>The median progression-free survival was 3.0 months (range 2.2-3.8), and median overall survival was 9.0 months (range 6.2-11.8) </plain></SENT>
<SENT sid="12" pm="."><plain>Cetuximab q2wks appears safe and effective in heavily pretreated patients and convenient in combination with q2wks CT schedules </plain></SENT>
</text></document>